Viridian Therapeutics Inc (VRDN)

Jan 8, 2025, 7:00 AM EST - 9 days ago

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Dec 19, 2024, 10:34 AM EST - 4 weeks ago

Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)

Dec 18, 2024, 10:56 AM EST - 4 weeks ago

Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation

Dec 17, 2024, 12:41 PM EST - 4 weeks ago

Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)

Dec 16, 2024, 7:10 AM EST - 4 weeks ago

Viridian Therapeutics' eye disorder drug meets late-stage study goal

Dec 16, 2024, 7:00 AM EST - 4 weeks ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Dec 13, 2024, 6:00 PM EST - 5 weeks ago

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Dec 4, 2024, 4:01 PM EST - 6 weeks ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 12, 2024, 7:00 AM EST - 2 months ago

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Oct 23, 2024, 4:02 PM EDT - 3 months ago

Viridian Therapeutics' Superior Prospects Make It A Buy

Sep 19, 2024, 12:54 PM EDT - 4 months ago

3 Small Biotech Stocks With The 'Big Mo' Right Now

AUPH CORT

Sep 11, 2024, 11:25 PM EDT - 4 months ago

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Sep 10, 2024, 5:09 PM EDT - 4 months ago

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Sep 10, 2024, 4:01 PM EDT - 4 months ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Sep 10, 2024, 7:18 AM EDT - 4 months ago

Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study

Sep 10, 2024, 7:00 AM EDT - 4 months ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Sep 9, 2024, 4:01 PM EDT - 4 months ago

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Aug 8, 2024, 8:15 AM EDT - 5 months ago

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 10:13 AM EDT - 6 months ago

Top 3 Health Care Stocks You May Want To Dump This Quarter

CPRX VRNA

Jul 29, 2024, 3:32 PM EDT - 6 months ago

3 Biotech Names With Potential Catalysts By Year End

CADL RCKT

Jul 25, 2024, 8:00 AM EDT - 6 months ago

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Jun 12, 2024, 10:29 AM EDT - 7 months ago

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Jun 11, 2024, 6:00 AM EDT - 7 months ago

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

May 31, 2024, 8:00 AM EDT - 8 months ago

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

May 10, 2024, 8:00 AM EDT - 9 months ago

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

May 8, 2024, 2:27 PM EDT - 9 months ago

Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 9 months ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

May 7, 2024, 7:33 PM EDT - 9 months ago

Pacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood Village

Apr 29, 2024, 8:00 AM EDT - 9 months ago

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Mar 5, 2024, 8:00 AM EST - 11 months ago

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Feb 27, 2024, 4:01 PM EST - 11 months ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 16, 2024, 8:00 AM EST - 1 year ago

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

Feb 6, 2024, 4:01 PM EST - 1 year ago

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 17, 2024, 10:00 PM EST - 1 year ago

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

Jan 8, 2024, 8:00 AM EST - 1 year ago

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

Jan 4, 2024, 8:00 AM EST - 1 year ago

Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 29, 2023, 11:23 AM EST - 1 year ago

Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023

Dec 26, 2023, 5:21 PM EST - 1 year ago

Wedbush's Laura Chico talks biotech investing in 2024

EWTX IBB NBIX XBI

Dec 18, 2023, 7:00 AM EST - 1 year ago

Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease

Dec 14, 2023, 1:24 PM EST - 1 year ago

Best Small-Cap Stocks to Buy for 2024 and Beyond

ARVN ASO BOOT FLYW GH IMVT PRVA

Dec 12, 2023, 8:00 AM EST - 1 year ago

Viridian: Market May Be Wrong In Its Disapproval

Nov 21, 2023, 8:00 AM EST - 1 year ago

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference

Nov 13, 2023, 4:01 PM EST - 1 year ago

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 8, 2023, 8:00 AM EST - 1 year ago

Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 3, 2023, 8:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology

Oct 30, 2023, 8:30 AM EDT - 1 year ago

Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing

Oct 26, 2023, 8:00 AM EDT - 1 year ago

Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease

Sep 27, 2023, 1:00 PM EDT - 1 year ago

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm